Compare ARLO & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | TYRA |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2018 | 2021 |
| Metric | ARLO | TYRA |
|---|---|---|
| Price | $13.33 | $25.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $24.00 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.82 | N/A |
| P/E Ratio | $82.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.05 | $12.40 |
| 52 Week High | $19.94 | $40.65 |
| Indicator | ARLO | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 49.78 |
| Support Level | $12.35 | $23.99 |
| Resistance Level | $14.06 | $27.87 |
| Average True Range (ATR) | 0.59 | 2.14 |
| MACD | 0.02 | 0.24 |
| Stochastic Oscillator | 48.50 | 64.22 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. Its cloud-based platform provides users with visibility, insight, and a powerful means to help protect and connect in real-time with the people and things that matter, from any location with a Wi-Fi or cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.